Based on the transcript of Amgen's Q1 2013 earnings call, here are the key points that influence the short-term impact on the stock price:

1. **Strong Financial Performance**: Amgen reported a 5% increase in revenues and a 22% increase in adjusted EPS, which are positive indicators of the company's financial health[5].
2. **Product Performance**: Key products such as Enbrel, Sensipar, Prolia, and XGEVA showed strong growth, with Enbrel sales up 11% year-over-year. Despite some seasonal softness in Prolia sales, the overall product portfolio performed well[5].
3. **Pipeline Advancements**: The company made significant progress in its pipeline, particularly with TVEC meeting its primary endpoint in malignant melanoma and plans to initiate pivotal trials for biosimilar products. These advancements suggest potential long-term growth drivers[5].
4. **Tax Rate and Guidance**: The company revised its full-year tax rate guidance downward to 11-12%, which positively impacts adjusted EPS guidance. This revision and the overall guidance reconfirmation are positive signals[5].
5. **Cash Flow and Balance Sheet**: Amgen generated strong free cash flow and has a solid balance sheet position, with plans to be in a net cash position by the end of the year[5].

Given these points:

- The strong financial performance, positive product sales, and significant pipeline advancements are likely to be viewed favorably by investors.
- The revised tax rate guidance and solid cash flow position add to the positive outlook.

Therefore, the stock is likely to experience a positive impact in the short term.

**Rating: 1**